rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GTCB 2007 ******

2.783 Posts
Pagina: «« 1 ... 85 86 87 88 89 ... 140 »» | Laatste | Omlaag ↓
  10. [verwijderd] 24 mei 2007 17:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Composite Indicator
    Trend Spotter TM Buy

    Short Term Indicators
    7 Day Average Directional Indicator Buy
    10 - 8 Day Moving Average Hilo Channel Hold
    20 Day Moving Average vs Price Buy
    20 - 50 Day MACD Oscillator Buy
    20 Day Bollinger Bands Hold

    Short Term Indicators Average: 60% - Buy
    20-Day Average Volume - 300965

    Medium Term Indicators
    40 Day Commodity Channel Index Hold
    50 Day Moving Average vs Price Buy
    20 - 100 Day MACD Oscillator Buy
    50 Day Parabolic Time/Price Buy

    Medium Term Indicators Average: 75% - Buy
    50-Day Average Volume - 361530

    Long Term Indicators
    60 Day Commodity Channel Index Hold
    100 Day Moving Average vs Price Buy
    50 - 100 Day MACD Oscillator Buy

    Long Term Indicators Average: 67% - Buy
    100-Day Average Volume - 417540

    Overall Average: 72% - Buy !!!!!!!
  13. [verwijderd] 24 mei 2007 17:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Posted by: DewDiligence
    In reply to: mblimon who wrote msg# 3596 Date:5/24/2007 9:43:46 AM
    Post #of 3606

    Management thinks GTC is the best-positioned company to play in the biogenerics/follow-on biologics arena for the simple reason that they have a cost advantage relative to all other serious players.

    I spent a lot of time talking to TN after the meeting about the various contenders in this area such as MNTA, NVS, TEVA, BRL, MYL, and MAXY.

  14. [verwijderd] 24 mei 2007 17:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Posted by: DewDiligence
    In reply to: jessellivermore who wrote msg# 3594 Date:5/24/2007 9:48:55 AM
    Post #of 3606

    >Dr Cox opined the case for Atryn to be clinically effective in DIC is much stronger than most people realize. They estimate this is a one billion dollar a year market in the AT-starved US market.

    The rationale for this viewpoint is laid out in message #3584 (#msg-19905539).

    As a side note, GTC needs to update the presentation slides and avoid silly inconsistencies: while one slide showed the addressable market for ATryn to be $1B+ for DIC/sepsis alone, another (older) slide showed the total ATryn market for all indications to be $500-700M.


  16. [verwijderd] 24 mei 2007 20:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GTC BIOTHERAPEUTICS REPORTS RESULTS OF 2007 ANNUAL MEETING
    UPDATES OF ATryn® CLINICAL DEVELOPMENT AND MARKET ESTIMATES



    FRAMINGHAM, MA – May 24, 2007 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) held its annual meeting of shareholders yesterday. Directors Robert W. Baldridge, James A. Geraghty, and Michael J. Landine were elected to three year terms on the board of directors. In addition, the proposed amendment and restatement of GTC’s 2002 Equity Incentive Plan was approved.



    During a presentation to shareholders following the business portion of the meeting, GTC updated its progress in the ATryn® program, including updating the estimated market in the acquired deficiency indication of disseminated intravascular coagulation, or DIC, in severe sepsis.



    “ATryn® has the potential to become an effective treatment to reduce the current mortality rate, which can be up to 50% in patients with disseminated intravascular coagulation associated with severe sepsis,” commented Suzanne Groet, Vice President of Therapeutic Development for GTC. “The needs of the approximately 500,000 patients spread equally between the U.S. and Europe who develop DIC associated with severe sepsis each year are not well met by current treatments. The opportunity for ATryn® is to ultimately demonstrate a significant reduction in mortality and displace the costs associated with current treatment options.”



    ATryn® is GTC’s recombinant form of human antithrombin. Antithrombin, produced in the liver and circulated in blood plasma, has both anticoagulant and anti-inflammatory properties. The recombinant form is able to be produced using GTC’s transgenic production platform, enabling large volume supply. ATryn® has been approved for use in Europe for the prophylactic treatment of deep vein thrombosis in hereditary antithrombin deficient patients undergoing surgical procedures. LEO Pharma A/S, GTC’s partner in the development and commercialization of ATryn® in Europe, Canada, and the Middle East, is initiating a Phase II dose ranging study in the DIC indication to establish an optimum dose to be used in a subsequent Phase III study. Recruitment into the Phase II study is anticipated to begin this quarter and is planned to take about 12 months.



    In evaluating the clinical and commercial opportunities in DIC in the U.S., GTC has determined that existing treatment options for severe sepsis are priced at a benchmark of approximately $10,000 per treatment, which if applied to DIC indicates a total potential U.S. market of $2 to 3 billion per year. GTC believes that ATryn® has the potential to achieve in excess of $1 billion of this potential DIC market in the U.S. alone, if successfully developed and approved for DIC associated with severe sepsis.



    GTC is also nearing completion of the clinical studies necessary to support the filing of a Biologics License Application for ATryn® in the HD indication planned for the first quarter of 2008. These studies include an evaluation of the incidence of deep vein thrombosis and thromboembolisms in 17 additional hereditary antithrombin deficient patients undergoing surgical and pregnancy procedures that will be treated with ATryn® and a non-inferiority comparison to a total of 35 historical records of patients undergoing similar procedures that have been treated with plasma-derived antithrombin products. GTC plans on releasing top line data from these studies in the fourth quarter of 2007. GTC is in discussions for potential commercial partnering in the US market for ATryn®.



    The full presentation from the annual shareholder meeting can be accessed at the GTC web site, www.gtc-bio.com.

  17. [verwijderd] 24 mei 2007 21:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    [This is pretty big news because the projection is being raised a lot, not a little. GTC now says that ATryn can achieve $1B in annual sales for just the DIC/sepsis indication in the U.S. (This is up from the prior guidance of $500-700M for all indications, worldwide.)

  19. [verwijderd] 24 mei 2007 21:30

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    vreemd ja,niet te volgen die amerikanen.Het ene aandeel gaat van 3 naar 25 en vervolgens net zo hard weer terug.En het andere aandeel is ondanks vele mooi berichten niet vooruit te branden.Toch een mooie update m.i en men blijft maar kloten binnen de marge van een paar centen.
2.783 Posts
Pagina: «« 1 ... 85 86 87 88 89 ... 140 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.070
AB InBev 2 5.518
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.730
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.750
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.753
Aedifica 3 916
Aegon 3.258 322.870
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.894
Agfa-Gevaert 14 2.051
Ahold 3.538 74.340
Air France - KLM 1.025 35.058
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.912
Allfunds Group 4 1.475
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.343
AMG 971 133.671
AMS 3 73
Amsterdam Commodities 305 6.697
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.015
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.784
Arcelor Mittal 2.034 320.748
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.240
ASML 1.766 107.952
ASR Nederland 21 4.500
ATAI Life Sciences 1 7
Atenor Group 1 498
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.684
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.403